988 an Open-Label Phase 2 Clinical Trial of Topical Remetinostat Gel for Basal Cell Carcinoma

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.1064
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Topical Therapy for Superficial Basal Cell Carcinoma

International Journal of Clinical & Experimental Dermatology
2017English

Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial

The Lancet Oncology
Oncology
2011English

PCN141 Quality of Life in Small Cell Lung Cancer: Results of an Open-Label Phase III Clinical Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Phase I Open Label Liver-Directed Gene Therapy Clinical Trial for Acute Intermittent Porphyria

Journal of Hepatology
Hepatology
2016English

An Open-Label, Phase 2 Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Meglumine Antimoniate Intralesional Infiltration for Localised Cutaneous Leishmaniasis: A Single Arm, Open Label, Phase II Clinical Trial

Memorias do Instituto Oswaldo Cruz
MedicineMicrobiology
2018English

A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension

Circulation Journal
MedicineCardiovascular MedicineCardiology
2011English

Ibrutinib as Initial Therapy for Elderly Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b/2 Trial

The Lancet Oncology
Oncology
2014English

Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum: An Open-Label, Single-Arm, Phase 2 Study

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy